Next-Generation Therapeutics for Inflammatory Bowel Disease

Parambir S. Dulai, William J. Sandborn*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Tumor necrosis factor (TNF) antagonists are the cornerstone of therapy for moderately to severely active inflammatory bowel disease (IBD). Although our understanding of pharmacokinetics, pharmacodynamics, and treatment optimization for these agents has evolved considerably over the past decade, a substantial majority of individuals fail to respond or lose response to TNF-antagonists over time. A need therefore remains for efficacious treatment options in these patients. Alternative immunological targets have now been identified, and several novel therapeutic agents are in development for IBD. In this review article, we discuss these novel therapeutic agents, with a particular focus on those demonstrated to be efficacious in phase 2 and 3 clinical trials. We further discuss considerations to be made when integrating these agents into routine practice over the next decade.

Original languageEnglish (US)
Article number51
JournalCurrent gastroenterology reports
Issue number9
StatePublished - Sep 1 2016
Externally publishedYes


  • Biologics
  • Etrolizumab
  • Tofacitinib
  • Ustekinumab
  • Vedolizumab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Next-Generation Therapeutics for Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this